FDA approves first treatment for rare disease in patients who receive stem cell transplant from blood or bone marrow - FDA Press Releases

The U.S. Food and Drug Administration today approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic veno-occlusive disease (VOD) with additional kidney or lung abnormalities after they receive a stem cell transplant from blood or bone marrow called hematopoietic stem cell transplantation (HSCT). This is the first FDA-approved therapy for treatment of severe hepatic VOD, a rare and life-threatening liver condition.

from Food and Drug Administration--Press Releases http://ift.tt/1V5jnVa
via IFTTT